Tag
Directory:
Tags:
- Everyone connected with healthcare supports interoperability saying it improves care, reduces medical errors and lowers costs
- But interoperability is a long way from reality and electronic patient records are only part of an answer
- Could Blockchain a technology disrupting financial systems resolve interoperability in healthcare?
- Blockchain is an open-source decentralized “accounting” platform that underpins crypto currencies
- Blockchain does not require any central data hubs, which in healthcare have been shown to be easily breached
- Blockchain technology creates a virtual digital ledger that could automatically record every interaction with patient data in a cryptographically verifiable manner
- Some experts believe that Blockchain could improve diagnosis, enhance personalised therapies, and prevent highly prevalent devastating and costly diseases
- Why aren’t healthcare leaders pursuing Blockchain with vigour?
Blockchain technology is disrupting financial systems by enhancing the reconciliation of global transactions and creating an immutable audit trail, which significantly enhances the ability to track information at lower costs, while protecting confidentiality. Could Blockchain do something similar for healthcare and resolve the challenges of interoperability by providing an inexpensive and enhanced means to immutably track, store, and protect a variety of patient data from multiple sources, while giving different levels of access to health professionals and the public?
You might not have heard of Blockchain, but probably you have heard of bitcoin; an intangible or crypto currency, which was created in 2008 when a programmer called Satoshi Nakamoto (a pseudonym) described bitcoin’s design in a paper posted to a cryptography e-mail list. Then in early 2009 Nakamoto released Blockchain: an open source, global decentralized accounting ledger, which underpins bitcoin by executing and immutably recording transactions without the need of a middleman. Instead of a centrally managed database, copies of the cryptographic balance book are spread across a network and automatically updated as transactions take place. Bitcoin gave rise to other crypto-currencies. Crypto currencies only exist as transactions and balances recorded on a public ledger in the cloud, and verified by a distributed group of computers.
A common misconception is that electronic patient records (EPR) resolve interoperability. They do not. EPRs were created to coordinate patient care inside healthcare settings by replacing paper records and filing cabinets. EPRs were not designed as open systems, which can easily collect, amalgamate and monitor a range of medical, genetic and personal information from multiple sources. To realize the full potential and promise of interoperability EPRs need to be easily accessible digitally, and in addition, have the capability to collect and manage remotely generated patient healthcare data as well as pharmacy and prescription information; family-health histories; genomic information and clinical-study data. To make this a reality existing data management conventions need to be significantly enhanced, and this is where Blockchain could help.
|
|
Directory:
Tags:
EUTROC
European Translational Research network in Ovarian CancerDirectory:
Expertise:
EUTROC (European Translational Research network in Ovarian Cancer) is a European cancer network addressing the fragmentation currently hindering translational research for cutting edge therapies in ovarian cancer.
It will strengthen European excellence in the diagnosis and treatment of OC.
The need to bring promising drug candidates and treatments into clinical settings is currently delayed by the lack of standardised protocols for preclinical animal studies, lack of suitable ovarian cancer models, lack of validated predictive biomarker diagnostics, and integrated appropriate management of translational research partners (including pharma and biotech companies).
Developing effective diagnostic and treatment strategies require structured joint efforts of experts on tumor immunology, epigenetics, pathology, bioinformatics, drug development and delivery, trial development, clinical oncology and gynecological oncology.
Leading European researchers and clinicians together with the pharmaceutical industry and biotech companies will focus on preclinical and clinical studies in ovarian cancer. Therefore new targets will be identified, validated and translated to new drugs and brought to clinical practice. Standardisation and harmonisation of laboratory practices and good clinical practice procedures will BE performed within the consortium.
The consortium combines expertise in clinical as well as preclinical research. Involved researchers are coordinating a number of investigator-initiated Phase I, II trials.The Network will build a platform for research and strong educational programs for the next generation of experts aimed at developing individualised patients benefit.
view this profile